Metabolic profiling-multitude of technologies with great research potential, but (when) will translation emerge?

International Journal of Epidemiology

Volumn 45, Issue 5, 2016, Pages 1311-1318

  Ala Korpela, Mika ^a,b   Smith, George Davey ^b  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAUSALITY; COMMERCIAL PHENOMENA; EDITORIAL; HUMAN; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; PEER REVIEW; PHENOTYPE; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE ANALYSIS; EPIDEMIOLOGY; LIFESTYLE; MOLECULAR EPIDEMIOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORGANIZATION AND MANAGEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIOECONOMICS; STANDARDS;

CAUSALITY; EPIDEMIOLOGIC METHODS; HUMANS; LIFE STYLE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR EPIDEMIOLOGY; PEER REVIEW; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIOECONOMIC FACTORS;

EID: 85015624074     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyw305     Document Type: Editorial

References (108)

1. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29: 1181-89
2. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011;40:387-426
3. Ala-Korpela M. Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool. Expert Rev Mol Diagn 2007;7:761-73
4. Ala-Korpela M. Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin Chem Lab Med 2008;46:27-42
5. Ala-Korpela M, Kangas AJ, Soininen P. Quantitative highthroughput metabolomics: a new era in epidemiology and genetics. Genome Med 2012;4:36
6. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 2015;8:192-206
7. Ala-KorpelaM. Metabolomics in cardiovascular medicine: Not personalised, not diagnostic. Eur J Prev Cardiol 2016 [epub ahead of print]. doi: 10.1177/2047487316664443
8. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013;9:280-99
9. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics-a review in human disease diagnosis. Anal Chim Acta 2010;659:23-33
10. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-38
11. Davey Smith G. Epidemiology, epigenetics and the 'Gloomy Prospect': embracing randomness in population health research and practice. Int J Epidemiol 2011;40:537-62
12. Hey SP, Kesselheim AS. Countering imprecision in precision medicine. Science 2016;353:448-49
13. Davey Smith G, Relton CL, Brennan P. Chance, choice and cause in cancer aetiology: individual and population perspectives. Int J Epidemiol 2016;45:605-13
14. Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. Nat Rev Genet 2009;10:872-78
15. Würtz P, Havulinna AS, Soininen P et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 2015;131:774-85
16. Würtz P, Mäkinen V-P, Soininen P et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012;61: 1372-80
17. Würtz P, Wang Q, Soininen P et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J Am Coll Cardiol 2016;67:1200-10
18. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006;355:2615-17
19. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011;123:551-65
20. Niiranen TJ, Vasan RS. Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. Exp Rev Cardiov Ther 2016;14:855-69
21. Robinson EB, Pourcain BS, Anttila Vet al. Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general population. Nat Genet 2016;48:552-55
22. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med 2007;4:e352
23. Baig F, Pechlaner R, Mayr M. Caveats of untargeted metabolomics for biomarker discovery. J Am Coll Cardiol 2016;68: 1294-96
24. Suhre K, Shin S-Y, Petersen A-K et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011;477:54-60
25. Suhre K, Wallaschofski H, Raffler J et al. A genome-wide association study of metabolic traits in human urine. Nat Genet 2011;43:565-69
26. Suhre K, Raffler J, Kastenmüller G. Biochemical insights from population studies with genetics and metabolomics. Arch Biochem Biophys 2016;589:168-76
27. Kettunen J, Tukiainen T, Sarin A-P et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012;44:269-76
28. Kettunen J, Demirkan A, Würtz P et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat Commun 2016;7:11122
29. Shin S-Y, Fauman EB, Petersen A-K et al. An atlas of genetic influences on human blood metabolites. Nat Genet 2014;46:543-50
30. Menni C, Kastenmüller G, Petersen A-K et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int J Epidemiol 2013;42:1111-19
31. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-53
32. Yet I, Menni C, Shin S-Y et al. Genetic influences on metabolite levels: a comparison across metabolomic platforms. PLoS One 2016;11:e0153672
33. Dona AC, Coffey S, Figtree G. Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment. Eur J Prev Cardiol 2016 [epub ahead of print]. doi: 10.1177/2047487316645469
34. Ala-Korpela M. 1H NMR spectroscopy of human blood plasma. Prog Nucl Magn Reson Spectrosc 1995;27:475-554
35. Mallol R, Rodriguez MA, Brezmes J, Masana L, Correig X. Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. Prog Nucl Magn Reson Spectrosc 2013;70:1-24
36. Mierisová S, Ala-Korpela M. MR spectroscopy quantitation: a review of frequency domain methods. NMR Biomed 2001;14:247-59
37. Dona AC, Jimenez B, Schäfer H et al. Precision highthroughput proton NMR spectroscopy of human urine, serum and plasma for large-scale metabolic phenotyping. Anal Chem 2014;86:9887-94
38. Demirkan A, Henneman P, Verhoeven A et al. Insight in genome-wide association of metabolite quantitative traits by exome sequence analyses. PLoS Genet 2015;11:e1004835
39. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014;129:553-61
40. Soininen P, Kangas AJ, Würtz P et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009;134:1781-85
41. van Duynhoven JPM, Jacobs DM. Assessment of dietary exposure and effect in humans: the role of NMR. Prog Nucl Magn Reson Spectrosc 2016;96:58-72
42. Lind MV, Savolainen OI, Ross AB. The use of mass spectrometry for analysing metabolite biomarkers in epidemiology: methodological and statistical considerations for application to large numbers of biological samples. Eur J Epidemiol 2016;31: 717-33
43. Quehenberger O, Dennis EA. The human plasma lipidome. N Engl J Med 2011;365:1812-23
44. Rankin NJ, Preiss D, Welsh P et al. The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis 2014;237:287-300
45. Mundra PA, Shaw JE, Meikle PJ. Lipidomic analyses in epidemiology. Int J Epidemiol 2016;45:1329-38
46. McKay J, Tkáč I. Quantitative in vivo neurochemical profiling in humans: where are we now? Int J Epidemiol 2016;45: 1339-50
47. Wahl S, Vogt S, Stückler F et al. Multi-omic signature of body weight change: results from a population-based cohort study. BMC Med 2015;13:48
48. Vogt S, Wahl S, Kettunen J et al. Characterization of the metabolic profile associated with serum 25-hydroxyvitamin D: a cross-sectional analysis in population-based data. Int J Epidemiol 2016;45:1469-81
49. Nelson SM, Panagiotou OA, Anic GM et al. Metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Epidemiol 2016;45:1458-68
50. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22
51. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014;23:R89-98
52. Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going? Int J Epidemiol 2015;44:379-88
53. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr 2016;103:965-78
54. Taylor AE, Burgess S, Ware JJ et al. Investigating causality in the association between 25(OH)D and schizophrenia. Sci Rep 2016;6:26496
55. Manousaki D, Mokry LE, Ross S, Goltzman D, Richards JB. Mendelian randomization studies do not support a role for vitamin D in coronary artery disease. Circ Cardiovasc Genet 2016;9:349-56
56. Ong JS, Cuellar-Partida G, Lu Yet al. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol 2016;45:1619-30
57. Mokry LE, Ross S, Ahmad OS et al. Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med 2015;12:e1001866
58. Wang Q, Kangas AJ, Soininen P et al. Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: observational and causal effect estimates. Int J Epidemiol 2015;44:623-37
59. Swerdlow DI, Kuchenbaecker KB, Shah S et al. Selecting instruments for Mendelian randomization in the wake of genomewide association studies. Int J Epidemiol 2016;45:1600-16
60. Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annu Rev Genomics Hum Genet 2015;16:327-50
61. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016 [epub ahead of print]. doi: 10.1016/S0140-6736(16)31357-5
62. Wang Q, Würtz P, Auro K et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol 2016;45:1445-57
63. Würtz P, Kangas AJ, Soininen P et al. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. J Am Coll Cardiol 2013;62: 1906-08
64. Würtz P, Wang Q, Kangas AJ et al. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med 2014;11:e1001765
65. Fischer K, Kettunen J, Würtz P et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of allcause mortality: an observational study of 17,345 persons. PLoS Med 2014;11:e1001606
66. Auro K, Joensuu A, Fischer K et al. A metabolic view on menopause and ageing. Nat Commun 2014;5:4708
67. Kujala UM, Mäkinen V-P, Heinonen I et al. Long-term leisuretime physical activity and serum metabolome. Circulation 2013;127:340-48
68. Würtz P, Cook S, Wang Q et al. Metabolic profiling of alcohol consumption in 9778 young adults. Int J Epidemiol 2016;45:1493-506
69. Würtz P, Wang Q, Niironen M et al. Metabolic signatures of birthweight in 18 288 adolescents and adults. Int J Epidemiol 2016;45:1539-50
70. Holmes MV, Dale CE, Zuccolo L et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014; 349:g4164
71. Mihaleva VV, van Schalkwijk DB, de Graaf AA et al. A systematic approach to obtain validated partial least square models for predicting lipoprotein subclasses from serum NMR spectra. Anal Chem 2014;86:543-50
72. Mihaleva VV, Korhonen S-P, van Duynhoven J, Niemitz M, Vervoort J, Jacobs DM. Automated quantum mechanical total line shape fitting model for quantitative NMR-based profiling of human serum metabolites. Anal Bioanal Chem 2014; 406:3091-102
73. Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics: state of the art in 2015. Front Bioeng Biotechnol 2015;3:1514
74. Vehtari A, Mäkinen V-P, Soininen P et al. A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data. BMC Bioinformatics 2007;8(Suppl 2):S8
75. Inouye M, Kettunen J, Soininen P et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol 2010;6:441
76. Mäkinen V-P, Soininen P, Kangas AJ et al. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med 2013;273:383-95
77. Mäkinen V-P, Tynkkynen T, Soininen P et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res 2012;11: 1782-90
78. Mäkinen V-P, Forsblom C, Thorn LM et al. Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (the FinnDiane Study). Cardiovasc Diabetol 2009;8:54
79. Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ. Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data. BMC Syst Biol 2011;5:21
80. Krumsiek J, Mittelstrass K, Do KT et al. Gender-specific pathway differences in the human serum metabolome. Metabolomics 2015;11:1815-33
81. Inouye M, Ripatti S, Kettunen J et al. Novel loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet 2012;8:e1002907
82. Ala-Korpela M, Kangas AJ, Inouye M. Genome-wide association studies and systems biology: together at last. Trends Genet 2011;27:493-98
83. Ritchie SC, Würtz P, Nath AP et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Systems 2015;1:293-301
84. Petersen A-K, Zeilinger S, Kastenmüller G et al. Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. HumMol Genet 2014;23:534-45
85. Krumsiek J, Bartel J, Theis FJ. Computational approaches for systems metabolomics. Curr Opin Biotechnol 2016;39: 198-206
86. Kastenmüller G, Raffler J, Gieger C, Suhre K. Genetics of human metabolism: an update. Hum Mol Genet 2015;24: R93-R101
87. Fearnley LG, Inouye M. Metabolomics in epidemiology: from metabolite concentrations to integrative reaction networks. Int J Epidemiol 2016;45:1319-28
88. Rankin NJ, Preiss D, Welsh P, Sattar N. Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future. Int J Epidemiol 2016;45:1351-71
89. Ioannidis JPA. Why most clinical research is not useful. PLoS Med 2016;13:e1002049
90. Clayton TA, Lindon JC, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006;440:1073-77
91. Assfalg M, Bertini I, Colangiuli D et al. Evidence of different metabolic phenotypes in humans. Proc Natl Acad Sci U S A 2008;105:1420-24
92. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant hostmicrobiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009;106:14728-33
93. Larmo PS, Kangas AJ, Soininen P et al. Effects of sea buckthorn and bilberry on serum metabolites differ according to baseline metabolic profiles in overweight women: a randomized crossover trial. Am J Clin Nutr 2013;98:941-51
94. Voora D, Shah SH. Pharmacometabolomics meets genetics. J Am Coll Cardiol 2016;67:1211-13
95. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG; EPIC-InterAct Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015;30:543-52
96. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical RandD. FEBS J 2007;274:1140-51
97. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov 2016;15:473-84
98. Hathout Y. Proteomic methods for biomarker discovery and validation. Are we there yet? Exp Rev Proteomics 2015;12: 329-31
99. Williams EG, Wu Y, Jha P et al. Systems proteomics of liver mitochondria function. Science 2016;352:aad0189
100. Billing AM, Ben Hamidane H, Bhagwat AM et al. Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells. J Proteomics 2017;150:86-97
101. Ioannidis JPA. Stealth research and Theranos: reflections and update 1 year later. JAMA 2016;316:389-90
102. Ioannidis JPA. Expectations, validity, and reality in omics. J Clin Epidemiol 2010;63:945-49
103. Rockhill B, Kawachi I, Colditz GA. Individual risk prediction and population-wide disease prevention. Epidemiol Rev 2000;22:176-80
104. Poste G. Bring on the biomarkers. Nature 2011;469:156-57
105. Ioannidis JPA, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res 2012;110:658-62
106. Moons KGM, Altman DG, Reitsma JB et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015;162:W1-73
107. Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 2016;16:525-37
108. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72